Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety
- 1 March 2009
- journal article
- research article
- Published by Elsevier BV in Endocrinology and Metabolism Clinics of North America
- Vol. 38 (1), 79-97
- https://doi.org/10.1016/j.ecl.2008.11.007
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Standards of Medical Care in Diabetes—2008Diabetes Care, 2008
- Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndromeAtherosclerosis, 2007
- Statin Safety and Drug Interactions: Clinical ImplicationsThe American Journal of Cardiology, 2006
- Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)The American Journal of Cardiology, 2005
- Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitorsThe American Journal of Cardiology, 2004
- Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agentExpert Opinion on Investigational Drugs, 2000
- The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patientsAtherosclerosis, 1995
- Lipids, diabetes, and coronary heart disease: Insights from the Framingham StudyAmerican Heart Journal, 1985
- The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study.Circulation, 1984
- Cholestyramine Promotes Receptor-Mediated Low-Density-Lipoprotein CatabolismNew England Journal of Medicine, 1980